Theoretically, both sMICA and TGF-β1 markedly reduce tumor recognition by the immune system and largely impair the tumoricidal effects of NKG2D-dependent processes by diminishing NK cell-mediated tumoricidal activity [4]. The gene discussed is TGFB1; the disease is neoplasm.